India, Aug. 12 -- TScan Therapeutics, Inc. (TCRX), a clinical-stage biotechnology company developing TCR-engineered T cell (TCR-T) therapies for cancer, has reported its second-quarter 2026 financial results and provided business updates, highlighting the Phase 3 advancement of TSC-101, encouraging Phase 1 ALLOHA data, commercial-ready manufacturing progress and expansion of its hematologic malignancy pipeline.
Recent Clinical & Corporate Updates:
-- A Phase 3 trial, evaluating TSC-101 in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation, dubbed ALLOHA-2, is underway.
The company expects to complete enrollment and report topline ALLOHA-2 data in mid-2028.
-- A Phase 1 interventional umbrella...